BIOMAT Database Logo BIOMAT Database Logo

Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. 2012

S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, M5S 3M2, ON, Canada. s.cadarette@utoronto.ca

We compared the patterns of osteoporosis medication prescribing between two provinces in Canada with different public drug coverage policies. Oral bisphosphonates were the primary drugs used, yet access to the second-generation oral bisphosphonates (alendronate, risedronate) was limited in one region. Implications of differential access to oral bisphosphonates warrants further study. BACKGROUND Approved therapies for treating osteoporosis in Canada include bisphosphonates, calcitonin, denosumab, raloxifene, and teriparatide. However, significant variation in access to these medications through public drug coverage exists across Canada. We sought to compare patterns of osteoporosis medication prescribing between British Columbia (BC) and Ontario. METHODS Using dispensing data from BC (PharmaNet) and Ontario (Ontario Drug Benefits), we identified all new users of osteoporosis medications aged 66 or more years from 1995/1996 to 2008/2009. We summarized the number of new users by fiscal year, sex, and index drug for each province. BC data were also stratified by whether drugs were dispensed within or outside public PharmaCare. RESULTS We identified 578,254 (n = 122,653 BC) eligible new users. Overall patterns were similar between provinces: (1) most patients received an oral bisphosphonate (93% in BC and 99% in Ontario); (2) etidronate prescribing declined after 2001/2002, reaching a low of 41% in BC and 10% in Ontario in 2008/2009; and (3) the proportion of males treated increased over time, from 7% in 1996/1997 to 25% in 2008/2009. However, we note major differences within versus outside the BC PharmaCare system. In particular, <2% of drugs dispensed within PharmaCare compared to 79% of drugs dispensed outside PharmaCare were for a second-generation bisphosphonate (alendronate or risedronate). CONCLUSIONS Oral bisphosphonates are the primary drugs used to treat osteoporosis in Canada. Prescribing practices changed over time as newer medications came to market, yet access to second-generation bisphosphonates through BC PharmaCare was limited. Implications of differential access to oral bisphosphonates warrants further study.

UI MeSH Term Description Entries
D008297 Male Males
D009864 Ontario A province of Canada lying between the provinces of Manitoba and Quebec. Its capital is Toronto. It takes its name from Lake Ontario which is said to represent the Iroquois oniatariio, beautiful lake. (From Webster's New Geographical Dictionary, 1988, p892 & Room, Brewer's Dictionary of Names, 1992, p391)
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D010818 Practice Patterns, Physicians' Patterns of practice related to diagnosis and treatment as especially influenced by cost of the service requested and provided. Clinical Practice Patterns,Physician's Practice Patterns,Clinical Practice Pattern,Pattern, Clinical Practice,Patterns, Clinical Practice,Practice Pattern, Clinical,Practice Patterns, Clinical,Practice Patterns, Physician's,Prescribing Patterns, Physician,Physician Practice Patterns,Physician Prescribing Pattern,Physician Prescribing Patterns,Physician's Practice Pattern,Physicians' Practice Pattern,Physicians' Practice Patterns,Practice Pattern, Physician's,Practice Pattern, Physicians',Practice Patterns, Physician,Prescribing Pattern, Physician
D011307 Drug Prescriptions Directions written for the obtaining and use of DRUGS. Drug Prescribing,Drug Prescription,Drug Prescribings,Prescribing, Drug,Prescribings, Drug
D001955 British Columbia A province of Canada on the Pacific coast. Its capital is Victoria. The name given in 1858 derives from the Columbia River which was named by the American captain Robert Gray for his ship Columbia which in turn was named for Columbus. (From Webster's New Geographical Dictionary, 1988, p178 & Room, Brewer's Dictionary of Names, 1992, p81-2)
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D004363 Drug Utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles. Utilization, Drug,Drug Utilizations,Utilizations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Income-based drug coverage in British Columbia: the impact on private and public expenditures.
November 2006, Healthcare policy = Politiques de sante,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Outcomes-based drug coverage in British Columbia.
January 2004, Health affairs (Project Hope),
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
British Columbia poised to reduce drug coverage.
March 2002, Canadian HIV/AIDS policy & law review,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Income-based drug coverage in British Columbia: the impact on access to medicines.
November 2006, Healthcare policy = Politiques de sante,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
British Columbia revamps process for determining drug coverage.
February 2011, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Drug-related overdose deaths in British Columbia and Ontario, 1992-2004.
January 2006, Canadian journal of public health = Revue canadienne de sante publique,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.
November 2006, Healthcare policy = Politiques de sante,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
January 2021, PloS one,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Trends in health care utilization in British Columbia following public coverage for tiotropium.
June 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
S M Cadarette, and G Carney, and D Baek, and N Gunraj, and J M Paterson, and C R Dormuth
Income-based drug coverage in british columbia: towards an understanding of the policy.
November 2006, Healthcare policy = Politiques de sante,
Copied contents to your clipboard!